Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13419616 | 0.89 | SCN9A (0.59) | ALDH1A1LMNAMAPTGPR119SCN9A | |
| SCHEMBL21644472 | 0.88 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL4369008 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTGPR119CSF1R | |
| SCHEMBL450240 | 0.85 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTGPR119SCN9A | |
| SCHEMBL23783010 | 0.85 | MAPT (0.54) | ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL30207533 | 0.85 | MAPT (0.54) | ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL2255441 | 0.85 | GPR119 (0.64) | ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL31216598 | 0.85 | GPR119 (0.64) | ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL31216608 | 0.85 | GPR119 (0.64) | ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL31333619 | 0.84 | MAPT (0.53) | ALDH1A1LMNAMAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | STAT6, RELA, NFKB2 | ALDH1A1 2263/4885LMNA 2990/4885MAPT 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.